Improved Pharma has collectively over 40 years’ experience in intellectual property matters including litigation, providing scientific support for claims, reproduction of claimed procedures, and analysis of materials. Improved Pharma also has developed skills in strategy and approaches to innovation.
Recently, the United States Court of Appeals for the Federal Circuit cited Dr. Byrn’s landmark paper on polymorph screening. They concluded that polymorphism is unpredictable and not obvious based on laboratory work and experiments. This ruling will likely have a significant impact on ANDA filing strategies.